Drug Approval | June 27, 2023
USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Supply readiness follows months of manufacturing to ensure timely and ample supply
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Urges Innovators to produce quality products that can be deployed at scale
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Subscribe To Our Newsletter & Stay Updated
